Date: 2015-06-25
Type of information: Nomination
Compound:
Company: Ultragenyx Pharmaceutical (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 25, 2015, Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the Board of Directors has elected Daniel G. Welch as the Company\'s non-executive Chairman of the Board effective June 18, 2015. Mr. Welch, Executive Partner at Sofinnova Ventures and former Chairman and Chief Executive Officer at InterMune, Inc., has served as an independent director to Ultragenyx since April 2015. In addition to serving as Chairman, Mr. Welch will also serve as a member of the Nominating and Corporate Governance Committee and the Compensation Committee. Mr. Welch has a distinguished track record as a life sciences executive, with over 30 years of experience across both multi-national pharmaceutical and biotechnology companies. Mr. Welch joined Sofinnova Ventures, a leading venture capital firm in biotechnology, in 2015 as an Executive Partner. From 2003 until the acquisition by Roche in October 2014, Mr. Welch was the Chairman, CEO and President of InterMune, where he built the development and commercial teams that delivered the successful approval of Esbriet in the U.S., Europe and other territories. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., President of the pharmaceutical division of Elan Corporation, PLC, and served in various senior management roles at Sanofi-Synthelabo (now Sanofi-Aventis) and its predecessor companies. Prior to this, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch serves on the board of directors of Seattle Genetics and served on the board of directors of Hyperion Therapeutics until the May 2015 acquisition of that company by Horizon Pharma plc. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.
Financial terms:
Latest news:
